Genentech, a member of the Roche Group, has broken ground on its first East Coast manufacturing facility in Holly Springs, North Carolina. This significant $700 million project is part of Roche's broader $50 billion investment in US manufacturing, infrastructure, and R&D. The new facility will create over 1,900 jobs and is designed to produce next-generation metabolic medicines, including treatments for obesity. The company chose North Carolina for its skilled workforce and strong academic institutions. This state-of-the-art site will incorporate advanced biomanufacturing technologies, automation, and digital capabilities. It is expected to be operational by 2029 and will enhance Roche's global manufacturing capacity and supply chain resilience. Roche aims to bring life-changing treatments to patients faster through innovative manufacturing. The company, founded in 1896, is a leader in biotechnology and diagnostics. Sustainability is an integral part of Roche's business, with a commitment to net zero by 2045.